The most popular versions of the Cas9 protein come from two bacteria, S. aureus and S. pyogenes, which means that most people could be immune to one of the world’s biggest advances in genetic engineering.
Sinogene, a biotech company based in Beijing has cloned a gene-edited dog in an attempt to treat cardiovascular disease.
Scientists have for the first time used CRISPR to disable a defective gene that causes amyotrophic lateral sclerosis, or Lou Gehrig’s disease, in mice, extending their lifespan by 25 percent.
Copenhagen Center for Glycomics has announced a collaboration with Desktop Genetics to analyse their novel CRISPR assay.
A biotech firm based in Boulder, CO is providing free access to MAD7 a novel enzyme in the gene editing field.
CRISPR Therapeutics is pioneering a new class of medicines, to conduct the first company-sponsored clinical trial of a CRISPR gene-edited therapy.
An adapted CRISPR technique could be used to treat incurable diseases, such as diabetes and muscular dystrophy, by turning up the volume on selected genes.
The US military invests $100m in genetic extinction technologies, after fears rise over channeling gene drives towards bioweaponry.
Harvard’s CRISPR pioneer, Chad Cowan has signed on to handle the preclinical work for new drugs slated to join the pipeline at a well-financed Mustang Bio.
In this podcast, Doudna talks about the ethical implications of changing the human genome, the importance of curiosity-driven science, and other topics.
Workarounds show robust mechanisms in place to keep surviving despite mutations.